Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04892953 · ClinicalTrials.gov registry record · Phase 2

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

A Phase 2 study of Stage III Lung Cancer AJCC v8 and Stage IIIB Lung Cancer AJCC v8, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
51
Enrollment target
1
Study location

NCT04892953: Recruiting Phase 2 study of Stage III Lung Cancer AJCC v8 and Stage IIIB Lung Cancer AJCC v8, sponsored by M.D. Anderson Cancer Center.

NCT04892953 is a Phase 2 study of Stage III Lung Cancer AJCC v8 and Stage IIIB Lung Cancer AJCC v8 that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 51 participants, below the 99-participant average among 40 other Stage III Lung Cancer AJCC v8 trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04892953, a Phase 2 study of Stage III Lung Cancer AJCC v8 and Stage IIIB Lung Cancer AJCC v8, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
51 participants
Enrollment target
1
Study location

Study Summary

This phase II trial finds out the effect of local consolidative therapy and durvalumab in treating patients with stage III non-small cell lung cancer that has 3 or fewer lesions of progression (oligoprogressive) and greater than 3 lesions of progression (polyprogressive) after chemoradiation and anti-PD-l1 therapy. Local consolidative therapy, such as surgery and/or radiation, after initial treatment may kill any remaining tumor cells. Immunotherapy with durvalumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving local consolidative therapy and durvalumab may help to control the disease.

Primary Outcome

The Kaplan-Meier product-limit estimate of the PFS function will be estimated and displayed for each treatment group. The median PFS time will be given with 95% confidence interval. Summaries of the number and percentage of patients experiencing a PFS event, and the type of event (Response Evaluation Criteria in Solid Tumors version 1.1 or death) will be provided. As comparative analysis, the one-sample log-rank test will be used to test difference in PFS between treatment and the historical con

Conditions Studied

Stage III Lung Cancer AJCC v8 Stage IIIB Lung Cancer AJCC v8 Stage IIIA Lung Cancer AJCC v8 Stage IIIC Lung Cancer AJCC v8 Stage IIIA Lung Non-Small Cell Cancer AJCC v7 Stage IIIB Lung Non-Small Cell Cancer AJCC v7 Stage III Lung Non-Small Cell Cancer AJCC v7

Interventions

  • DRUG Carboplatin
  • BIOLOGICAL Durvalumab
  • DRUG Gemcitabine
  • DRUG Nab-paclitaxel
  • PROCEDURE Local Consolidation Therapy

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2021-07-07
Est. Completion 2026-09-30
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What NCT04892953 shows while recruiting

NCT04892953 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 99-participant average among 40 other Stage III Lung Cancer AJCC v8 trials with a reported enrollment target (48% lower).

The record links to 7 conditions, with Stage III Lung Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT04892953 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT04892953 about?

NCT04892953 is a clinical study titled "Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy". This phase II trial finds out the effect of local consolidative therapy and durvalumab in treating patients with stage III non-small cell lung cancer that has 3 or fewer lesions of progression (oligoprogressive) and greater than 3 lesions of progression (polyprogressive) after chemoradiation and ant...

What is the current status of trial NCT04892953?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2021-07-07. Estimated completion is 2026-09-30.

What conditions does trial NCT04892953 study?

This clinical trial studies the following conditions: Stage III Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7.

What interventions are being tested in trial NCT04892953?

The interventions under investigation include: Carboplatin (DRUG), Durvalumab (BIOLOGICAL), Gemcitabine (DRUG), Nab-paclitaxel (DRUG), Local Consolidation Therapy (PROCEDURE).

Who is sponsoring clinical trial NCT04892953?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04892953 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage III Lung Cancer AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04892953's enrollment target sits among peer trials

51 15th of 40 higher than 25 of 40 other Stage III Lung Cancer AJCC v8 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stage III Lung Cancer AJCC v8 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02701153 · 51 participants · NA

    Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort

  • NCT03663790 · 51 participants · NA

    Effects of Gait Retraining on Lower Extremity Biomechanics

  • NCT03874052 · 51 participants · Phase 1

    Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

  • NCT04704661 · 51 participants · Phase 1

    Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT04892953

Source: ClinicalTrials.gov NCT04892953, the US trial registry maintained by the National Library of Medicine. NCT04892953 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.